Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Marin JJG, Al-Abdulla R, Lozano E, Briz O, Bujanda L, Banales M. Mechanisms of resistance to Chemotherapy in Gastric Cancer. Anticancer Agents Med Chem. 2016;16(3):318–34.

Article  PubMed  CAS  Google Scholar 

Zhang D, Fan D. New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives. Future Oncol. 2010;6:527–37.

Article  PubMed  CAS  Google Scholar 

DIgklia A, Wagner AD. Advanced gastric cancer: current treatment landscape and future perspectives. World J Gastroenterol. 2016.

Keehn RJ, Higgins GA. Chemotherapy for gastric cancer. Lancet. 1981;1(8215):323.

Article  PubMed  CAS  Google Scholar 

Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4(4):307–20.

Article  PubMed  CAS  Google Scholar 

Shi WJ, Gao JB. Molecular mechanisms of chemoresistance in gastric cancer. World J Gastrointest Oncol. 2016;8(9):673.

Article  PubMed  PubMed Central  Google Scholar 

Huang H, Han Y, Zhang C, Wu J, Feng J, Qu L, et al. HNRNPC as a candidate biomarker for chemoresistance in gastric cancer. Tumour Biol. 2016;37(3):3527–34.

Article  PubMed  CAS  Google Scholar 

Chen SH, Chang JY. New insights into mechanisms of cisplatin resistance: from tumor cell to microenvironment. Int J Mol Sci. 2019;20(17).

Mora Y, Reyes ME, Zanella L, Mora B, Buchegger K, Ili C, et al. Resistance to platinum-based cancer drugs: a special focus on epigenetic mechanisms. Pharmacogenomics. 2021;22(12):777–90.

Article  PubMed  CAS  Google Scholar 

Reyes ME, de La Fuente M, Hermoso M, Ili CG, Brebi P. Role of CC chemokines Subfamily in the platinum drugs Resistance Promotion in Cancer. Front Immunol. 2020.

Mora-Lagos B, Cartas-Espinel I, Riquelme I, Parker AC, Piccolo SR, Viscarra T et al. Functional and transcriptomic characterization of cisplatin-resistant AGS and MKN-28 gastric cancer cell lines. PLoS ONE. 2020.

Aldinucci D, Borghese C, Casagrande N. The CCL5/CCR5 Axis in Cancer Progression. Cancers (Basel). 2020;12(7).

Ryu H, Baek S, Moon J, Jo I, Kim N, Lee H. CC motif chemokine receptors in gastric cancer (review). Mol Clin Oncol. 2017.

Jiao X, Nawab O, Patel T, Kossenkov AV, Halama N, Jaeger D et al. Recent advances targeting CCR5 for cancer and its role in immuno-oncology. Cancer Res. 2019.

Aldinucci D, Casagrande N. Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer. Int J Mol Sci [Internet]. 2018;19(5):1477. https://pubmed.ncbi.nlm.nih.gov/29772686

Mukaida N, Tanabe Y, Baba T. Chemokines as a conductor of bone marrow microenvironment in chronic myeloid leukemia. Int J Mol Sci. 2017;18(8):1824.

Article  PubMed  PubMed Central  Google Scholar 

Velasco-velazquez M, Jiao X, Fuente MD, La, Pestell TG. CCR5 antagonist blocks metastasis of basal breast Cancer cells CCR5 antagonist blocks metastasis of basal breast Cancer cells. 2012;(December 2015).

Cambien B, Richard-Fiardo P, Karimdjee BF, Martini V, Ferrua B, Pitard B, et al. CCL5 neutralization restricts Cancer Growth and Potentiates the Targeting of PDGFRβ in Colorectal Carcinoma. PLoS ONE. 2011;6(12):e28842.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yang T, Chen M, Yang X, Zhang X, Zhang Z, Sun Y, et al. Down-regulation of KLF5 in cancer-associated fibroblasts inhibit gastric cancer cells progression by CCL5/CCR5 axis. Cancer Biol Ther. 2017;18(10):806–15.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pervaiz A, Zepp M, Mahmood S, Ali DM, Berger MR, Adwan H. CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer. Cell Oncol. 2019;42(1):93–106.

Article  CAS  Google Scholar 

Ding H, Zhao L, Dai S, Li L, Wang F, Shan B. CCL5 secreted by tumor associated macrophages may be a new target in treatment of gastric cancer. Biomed Pharmacotherapy. 2016.

Mencarelli A, Graziosi L, Renga B, Cipriani S, D’Amore C, Francisci D et al. CCR5 antagonism by maraviroc reduces the potential for gastric cancer cell dissemination. Transl Oncol. 2013.

Durán-Jara E, del Campo M, Gutiérrez V, Wichmann I, Trigo C, Ezquer M, et al. Lactadherin immunoblockade in small extracellular vesicles inhibits sEV-mediated increase of pro-metastatic capacities. Biol Res. 2024;57(1):1.

Article  PubMed  PubMed Central  Google Scholar 

Lobos-González L, Aguilar L, Diaz J, Diaz N, Urra H, Torres VA et al. E-cadherin determines Caveolin-1 tumor suppression or metastasis enhancing function in melanoma cells. Pigment Cell Melanoma Res [Internet]. 2013;26(4):555–70. https://onlinelibrary.wiley.com/doi/abs/https://doi.org/10.1111/pcmr.12085

Lobos-Gonzalez L, Aguilar-Guzmán L, Fernandez JG, Muñoz N, Hossain M, Bieneck S et al. Caveolin-1 is a risk factor for postsurgery metastasis in preclinical melanoma models. Melanoma Res [Internet]. 2014;24(2). https://journals.lww.com/melanomaresearch/fulltext/2014/04000/caveolin_1_is_a_risk_factor_for_postsurgery.3.aspx

Xu H, Bin, Shen FM, Lv QZ. Celecoxib enhanced the cytotoxic effect of cisplatin in chemo-resistant gastric cancer xenograft mouse models through a cyclooxygenase-2-dependent manner. Eur J Pharmacol. 2016.

Singh SK, Mishra MK, Eltoum IEA, Bae S, Lillard JW, Singh R. CCR5/CCL5 axis interaction promotes migratory and invasiveness of pancreatic cancer cells. Sci Rep. 2018;8(1):1323.

Article  PubMed  PubMed Central  Google Scholar 

Halama N, Zoernig I, Berthel A, Grabe N, Falk CS, Jaeger D, et al. Tumoral Immune Cell Exploitation in Colorectal Cancer metastases can be targeted effectively by Anti-CCR5 therapy in Cancer patients Article Tumoral Immune Cell Exploitation in Colorectal Cancer metastases can be targeted effectively by Anti-CCR5 therapy. Cancer Cell. 2016;29(4):587–601.

Article  PubMed  CAS  Google Scholar 

Jones VS, Huang RY, Chen LP, Chen ZS, Fu L, Huang RP. Cytokines in cancer drug resistance: cues to new therapeutic strategies. Biochim Biophys Acta Rev Cancer. 2016;1865(2):255–65.

Article  CAS  Google Scholar 

Pasquier J, Gosset M, Geyl C, Hoarau-Véchot J, Chevrot A, Pocard M et al. CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer. Mol Cancer. 2018.

Zhou B, Sun C, Li N, Shan W, Lu H, Guo L, et al. Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways. Int J Oncol. 2016;48(5):2087–97.

Article  PubMed  CAS  Google Scholar 

Jones VS, Huang RY, Chen LP, Chen ZS, Fu L, Huang RP. Cytokines in cancer drug resistance: cues to new therapeutic strategies. Biochimica et Biophysica Acta - Reviews on Cancer; 2016.

Casagrande N, Borghese C, Visser L, Mongiat M, Colombatti A, Aldinucci D. CCR5 antagonism by maraviroc inhibits hodgkin lymphoma microenvironment interactions and xenograft growth. Haematologica. 2019.

Rocha CRR, Silva MM, Quinet A, Cabral-neto JB, Menck FMC. DNA repair pathways and cisplatin resistance: an intimate relationship. Clinics. 2018.

Wang P, Cui J, Wen J, Guo Y, Zhang L, Chen X. Cisplatin induces HepG2 cell cycle arrest through targeting specific long noncoding RNAs and the p53 signaling pathway. Oncol Lett. 2016;12(6):4605–12.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yip HT, Chopra R, Chakrabarti R, Veena MS, Ramamurthy B, Srivatsan ES, et al. Cisplatin-Induced growth arrest of Head and Neck Cancer cells correlates with increased expression of p16 and p53. Arch Otolaryngol Head Neck Surg. 2006;132(3):317.

Article  PubMed  Google Scholar 

Xu ZY, Loignon M, Han FY, Panasci L, Aloyz R. Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis. J Pharmacol Exp Ther. 2005;314(2):495–505.

Article  PubMed  CAS  Google Scholar 

Li Lya, Guan Y di, Chen X, sha, Yang J ming, Cheng Y. DNA Repair Pathways in Cancer Therapy and Resistance. Front Pharmacol. 2021;11.

Jiao X, Velasco-Velazquez MA, Wang M, Li Z, Rui H, Peck AR et al. CCR5 governs DNA damage repair and breast cancer stem cell expansion. Cancer Res. 2018.

Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–26.

Article  PubMed  CAS  Google Scholar 

Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of Cancer Drug Resistance: a brief review. Adv Pharm Bull. 2017;7(3):339–48.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Housman G, Byler S, Heerboth S, Lapinska K, Longacre M, Snyder N, et al. Drug resistance in cancer: an overview. Cancers. 2014;6:1769–92.

Article  PubMed  PubMed Central  Google Scholar 

Sandoval-Bórquez A, Polakovicova I, Carrasco-Véliz N, Lobos-González L, Riquelme I, Carrasco-Avino G et al. MicroRNA-335-5p is a potential suppressor of metastasis and invasion in gastric cancer. Clin Epigenetics [Internet]. 2017;9(1):114. https://doi.org/10.1186/s13148-017-0413-8

Borgna V, Lobos-González L, Guevara F, Landerer E, Bendek M, Ávila R, et al. Targeting antisense mitochondrial noncoding RNAs induces bladder cancer cell death and inhibition of tumor growth through reduction of survival and invasion factors. J Cancer. 2020;11(7):1780–91.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Ortega L, Lobos-González L, Reyna-Jeldes M, Cerda D, De la Fuente-Ortega E, Castro P, et al. The Ω-3 fatty acid docosahexaenoic acid selectively induces apoptosis in tumor-derived cells and suppress tumor growth in gastric cancer. Eur J Pharmacol. 2021;896:173910.

Article  PubMed  CAS  Google Scholar 

Nunes AS, Barros AS, Costa EC, Moreira AF, Correia IJ. 3D tumor spheroids as in vitro models to mimic in vivo human solid tumors resistance to therapeutic drugs. Biotechnol Bioeng. 2019;116(1):206–26.

Article  PubMed  CAS